A Phase 2, Open-Label Study of the Safety and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck, Lung, or Esophagus
A study for patients with advanced skin cancer of the head and neck, lung or esophagus using study drug Selinexor (KPT-330)
Sponsor: Karyopharm Therapeutics, Inc
Enrolling: Male and Female Patients
IRB Number: AAAN9156
U.S. Govt. ID: NCT02213133
Contact: Sewanti Limaye: 646-317-6228 / sal2192@columbia.edu
Additional Study Information: The purpose of this study is to examine the effects of KPT-330 on patients with an advanced form of skin cancer called Squamous Cell Cancer (SCC) of the head and neck, lung, or esophagus. The study drug KPT-330 is an investigational drug that
This study is closed
Investigator
Sewanti Limaye, MD
Do You Qualify?
Do you have a confirmed diagnosis of SCC of the head and neck, lung, or esophagus? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Sewanti Limaye
sal2192@columbia.edu
646-317-6228
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE